Key result
Pre-treatment with intracoronary low-dose urokinase before direct PTCA significantly reduced the frequency of acute restenosis compared to PTCA alone (68.6% vs 80.1%) in patients with acute myocardial infarction.
Why the study?
Does pre-treatment with intracoronary low-dose urokinase before direct PTCA reduce the frequency of acute restenosis in patients with acute myocardial infarction?
Population
272 patients with acute myocardial infarction within 12 hours of symptom onset who had initially successful…
Comparison
Intracoronary urokinase administered over 10 to… vs Direct percutaneous coronary angioplasty alone…
Design
Cohort
Follow-up
30 minutes for acute restenosis; 14±5.5 days for follow-up…
Authors
Loading...
May support urokinase pre-PTCA in select AMI; hypothesis-generating, requires RCTs before practice change.
Cohort (n=272)
No
Does pre-treatment with intracoronary low-dose urokinase before direct PTCA reduce the frequency of acute restenosis in patients with acute myocardial infarction?
Absolute Event Rate: 68.6% vs 80.1%
p-value: p=<0.01
Pre-treatment with intracoronary low-dose urokinase before direct PTCA significantly reduces the frequency of acute restenosis in AMI patients with large coronary thrombi.
Oshima et al. (1999) conducted a cohort in Acute Myocardial Infarction (n=272). Intracoronary urokinase vs. Direct PTCA alone was evaluated on Frequency of acute restenosis during the first 30 minutes after successful PTCA (p=<0.01). Pre-treatment with intracoronary low-dose urokinase before direct PTCA significantly reduced the frequency of acute restenosis compared to PTCA alone (68.6% vs 80.1%) in patients with acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: